The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors

BACKGROUND: Pharmacokinetic (PK) studies suggest that talazoparib is primarily eliminated unchanged via renal excretion. The current study investigated how varying degrees of renal impairment may affect the PK of talazoparib, and evaluated the safety and tolerability of talazoparib, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Durairaj, Chandrasekar, Chakrabarti, Jayeta, Ferrario, Cristiano, Hirte, Holger W., Babu, Sunil, Piha-Paul, Sarina A., Plotka, Anna, Hoffman, Justin, Shi, Haihong, Wang, Diane D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249284/
https://www.ncbi.nlm.nih.gov/pubmed/33686631
http://dx.doi.org/10.1007/s40262-020-00983-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249284/
https://www.ncbi.nlm.nih.gov/pubmed/33686631
http://dx.doi.org/10.1007/s40262-020-00983-y

Ejemplares similares